NeuroMetrix, Inc. (NASDAQ:NURO) Short Interest Update

NeuroMetrix, Inc. (NASDAQ:NURO) was the recipient of a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 1,600 shares, a drop of 36.0% from the February 28th total of 2,500 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily volume of 18,000 shares, the short-interest ratio is currently 0.1 days.

NeuroMetrix Stock Performance

Shares of NURO traded up $0.07 during midday trading on Monday, hitting $4.50. 3,387 shares of the company traded hands, compared to its average volume of 12,325. The stock has a market cap of $9.26 million, a price-to-earnings ratio of -0.98 and a beta of 2.15. NeuroMetrix has a 52 week low of $2.66 and a 52 week high of $4.73. The firm has a 50 day moving average of $4.35 and a 200-day moving average of $4.15.

Analyst Ratings Changes

Separately, StockNews.com started coverage on shares of NeuroMetrix in a report on Friday. They issued a “sell” rating for the company.

Institutional Trading of NeuroMetrix

A hedge fund recently bought a new stake in NeuroMetrix stock. Renaissance Technologies LLC bought a new position in NeuroMetrix, Inc. (NASDAQ:NURO) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 11,560 shares of the medical device company’s stock, valued at approximately $46,000. Renaissance Technologies LLC owned 0.57% of NeuroMetrix as of its most recent filing with the SEC. 19.40% of the stock is owned by institutional investors.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.